Xact Kapitalforvaltning’s Myriad Genetics MYGN Stock Holding History

Xact Kapitalforvaltning’s Portfolio MYGN Stock Details MYGN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2020 Q1	$172K	Hold	11,988	–	–	﹤0.01%	1229
2019 Q4	$326K	Hold	11,988	–	–	0.01%	1205
2019 Q3	$343K	Hold	11,988	–	–	0.01%	1132
2019 Q2	$333K	Hold	11,988	–	–	0.01%	1162
2019 Q1	$398K	Sell	11,988 -6,000	-33%	-$183K	0.01%	1061
2018 Q4	$523K	Buy	17,988 +6,000	+50%	+$216K	0.01%	851
2018 Q3	$551K	Hold	11,988	–	–	0.01%	902
2018 Q2	$448K	Buy	11,988 +1,000	+9%	+$33.8K	0.01%	1015
2018 Q1	$325K	Buy	10,988 +3,400	+45%	+$115K	0.01%	1184
2017 Q4	$261K	Buy	+7,588	New	+$256K	0.01%	1045

Other funds holding MYGN

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

EARNEST Partners Atlanta, Georgia $24.3B AUM 34.41% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

DGI

Disciplined Growth Investors Minneapolis, Minnesota $4.89B AUM 33.85% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return

CCM

Camber Capital Management Boston, Massachusetts $1.07B AUM 8.19% 1-Year Est. Return

Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

Xact Kapitalforvaltning's MYGN Position: Q1 2020 in Review

Xact Kapitalforvaltning held its Myriad Genetics (MYGN) position steady in Q1 2020 at 11,988 shares worth $172K. The position accounts for ﹤0.01% of the portfolio, ranked #1229.

Xact Kapitalforvaltning first reported a position in MYGN in Q4 2017 and has held it in 10 quarters since. The position peaked at $551K in Q3 2018. 190 funds tracked by Wall St. Rank hold MYGN as of Q1 2020.

Xact Kapitalforvaltning held 11,988 shares of Myriad Genetics worth $172K as of Q1 2020.
Xact Kapitalforvaltning left its Myriad Genetics share count unchanged in Q1 2020.
Myriad Genetics made up ﹤0.01% of Xact Kapitalforvaltning's portfolio in Q1 2020, its #1229 holding.
Xact Kapitalforvaltning first reported a position in Myriad Genetics in Q4 2017 and has held it in 10 quarters since.
Xact Kapitalforvaltning's Myriad Genetics position peaked at $551K in Q3 2018.
190 funds tracked by Wall St. Rank held Myriad Genetics as of Q1 2020.

Based on Xact Kapitalforvaltning's 13F filing for Q1 2020, filed 14 May 2020.